Study finds disparities in access to insulin pumps among youth with type 1 diabetes

Over the past 20 years, despite the overall increase in the use of insulin pumps, there have been few improvements in the ethnic, racial and socioeconomic inequities in insulin pump use among youth with type 1 diabetes, according to a new study presented Tuesday, June 14 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Researchers develop pancreatic beta-cell restoring therapy for treating type 1 diabetes

Researchers have successfully treated type 1 diabetes in mice using pancreatic beta-cell, target-specific, chimeric antigen-receptor (CAR) regulatory T cells (Tregs), and demonstrated the feasibility of their approach to treat the human condition according to data being presented Monday, June 13 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Study finds long-term 10% weight loss with anti-obesity medications and lifestyle changes

A new study finds overweight and obese people maintained an average weight loss of 10.6% over 3 to 5 years with a program of lifestyle changes in combination with anti-obesity medications. Weight loss of more than 10% provides significant health benefits, according to researchers who are presenting their findings Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Longer treatment with puberty-delaying medication in transgender youth leads to lower bone mineral density

A longer duration of treatment with puberty-delaying medications among transgender youth is associated with lower bone mineral density, according to a new study that will be presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Endocrine-disrupting chemical exposure in womb impact fear, anxiety behavior in rats

Prenatal exposure to endocrine-disrupting chemicals found in everyday products may interfere with the developing offspring’s brain, according to a rat study being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Adult growth hormone deficiency increases medical costs, risk of additional health conditions

Growth hormone deficiency (GHD) among adults is associated with greater medical costs and an increased rate of other health conditions compared with those without GHD, according to industry-sponsored research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

AI can be used to identify benign thyroid nodules and reduce unnecessary biopsies

Artificial intelligence (AI) can be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a new study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Testosterone improves quality of life, sexual function, and delayed verbal recall in men with uncontrolled type 2 diabetes

Testosterone replacement therapy improved sexual symptoms, libido, symptom severity, delayed verbal recall and overall quality of life among people with poorly controlled type 2 diabetes and hypogonadism, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Drinking coffee does not hinder the absorption of liquid thyroid medication

A new study conducted by Vertice Pharma confirms the absorption of an oral levothyroxine sodium solution (Thyquidity® 100g/ 5mL) was not affected by consuming coffee 5 minutes after the dose, according to research being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Probiotic bacteria may enhance tamoxifen effectiveness in treatment of ER+ breast cancer

Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests a new study presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Teens ate less ultra-processed food consumption during pandemic, reversing trend of three decades

For the first time in the last 30 years, the consumption of ultra-processed foods among teenagers in the United States declined during the COVID-19 pandemic, according to a new study presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

COVID-19 vaccination appears to be safe for patients treated for hypothyroidism

Inactivated and mRNA COVID-19 vaccines appear to be safe for patients treated for hypothyroidism,
according to a new study being presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga. The study found these vaccines do not cause significant fluctuations in thyroid function and are not associated with increased risks of emergency department visits or unscheduled hospitalizations.

Addressing stress and postpartum symptoms early may reduce risk for type 2 diabetes in women with gestational diabetes

Addressing stress early on in postpartum women who recently experienced gestational diabetes might help curb an increased risk for type 2 diabetes, according to research being presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Chemicals in personal care products cause harmful effects in breast cancer cells from Black women

Chemicals called parabens, which are found in widely used hair and personal care products, cause harmful effects in breast cancer cells from Black women, according to a new study being presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Suppressed ovarian follicle development in women with obesity may explain reduced fertility

Women with obesity, even those with regular menstrual cycles, have suppressed ovarian follicle development and reduced production of reproductive hormones, which may underlie reduced fertility, according to a new study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Analysis finds little evidence of heart problems in men undergoing testosterone treatment

Previous clinical trials have provided insufficient evidence to decide whether testosterone causes heart problems in men during the first year of treatment, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., and published in The Lancet Healthy Longevity.